Research published in @NatureComms found our lead in vivo gene therapy candidate resolved biochemical and hepatic histological markers of #HT1 in a large animal model. https://t.co/TEhahMl5d1
We’re advancing our novel gene therapy development programs for genetic skin disorders & metabolic liver diseases, including hereditary tyrosinemia type 1, or HT1. Learn more about #HT1 from NOTA, the Network of Tyrosinemia Advocates: https://t.co/nzZRGBvuRQ
Attending the #DebraCareConference? Be sure to say hello to the Castle Creek Biosciences team at our booth. We can answer questions about the RDEB clinical study program for recessive dystrophic #epidermolysisbullosa. #RDEB#WeFightEB
The @debraOfAmerica Care Conference begins today! We are honored to be a sponsor of this multi-day event, designed for #epidermolysisbullosa families & caregivers to engage with other EB families and professionals. Find details: https://t.co/kFJ4q0iAO7 #WeFightEB
We are on-site in Indianapolis for the @SocietyPedsDerm 47th Annual Meeting. We are a proud sponsor of #SPD2022, addressing the latest advancements in education, research and care of skin diseases for all pediatric age groups.
#SaveTheDate We are looking forward to #SPD2022, @SocietyPedsDerm 47th Annual Meeting in Indianapolis from July 7-10.
Explore the schedule, speakers, and session topics here: https://t.co/ayo7HbPVaR
This month we join our colleagues & industry partners in celebrating #PrideMonth! We believe #inclusion drives #innovation, and we’re committed to a #diverse workforce who are passionate about making a difference for patients & families living with genetic diseases.
Happy #FathersDay! Celebrating the incredible dads everywhere and especially those on our Castle Creek Biosciences team. We are inspired by your spirit and strength and appreciate everything you do!
The @BIOConvention is back! Our President & CEO Matt Gantz is in San Diego for #BIO22 this week, where he will present a corporate overview on 6/15 & join with global thought leaders in science, business & policy. Details: https://t.co/cmCOK1jAp7 @IAmBiotech#BIOConvention
Today we announced $112.8M in financing to support the expected completion of our Phase 3 study for #RDEB, and the advancement of our in vivo candidate for hereditary tyrosinemia type 1 towards submission of an IND application.
Find details: https://t.co/hYwFRTVp48
Thanks to @SocInvestDerm for planning this week’s 2022 Annual Meeting, a gathering of exceptional experts in #dermatology discussing the latest in the science of #skinhealth & disease. #SID22.
For details visit https://t.co/IAE5vXxEK1
#ASGCT22 begins today! We have two abstracts accepted for presentation this week highlighting our clinical program in recessive dystrophic #epidermolysisbullosa. Looking forward to sharing this important data with the gene & #celltherapy scientific community.
@ASGCTherapy
Nurses play an essential role in supporting patients & families during their most challenging moments. This week in recognition of #NursesWeek, we extend our appreciation to nurses everywhere for their enduring strength, compassion, and commitment to care. #ThankYouNurses
Happy #MothersDay to the extraordinary moms in our lives, in our communities and on our Castle Creek Biosciences team. Today we celebrate you and all you do.
#Pediatrics360 is an engaging, interactive educational experience designed for pediatricians and dermatologists with an interest in pediatric #dermatology. We’re proud to be a sponsor & virtually join with fellow #derm thought leaders this weekend.
https://t.co/4VUVMiE2aQ
Classical Ehlers-Danlos syndrome (EDS) is a genetic connective tissue disorder that is caused by defects in collagen. May is #EhlersDanlosSyndrome Awareness Month, and we’re joining @TheEDSociety in creating global awareness of EDS and the urgent need for treatment options.